Relay Therapeutics
Relay Therapeutics Advances PI3K Inhibitor for Breast Cancer Subgroup with Promising Early Trial Results
Relay Therapeutics, PI3K inhibitor, breast cancer, RLY-2608, metastatic breast cancer, PI3Ka mutations, clinical trial
Relay Therapeutics Partners with Elevar Therapeutics in $500M Deal for Lirafugratinib in Rare Cancer Treatment
Relay Therapeutics, Elevar Therapeutics, Lirafugratinib, FGFR2-Driven Cholangiocarcinoma, Rare Cancer Treatment, Biotech Partnership
Relay Therapeutics Announces Additional Layoffs to Achieve $50M Annual Savings
Relay Therapeutics, layoffs, cost-cutting, biotech industry, workforce reduction
Relay Therapeutics Announces 10% Workforce Reduction to Streamline Research Organization
Relay Therapeutics, layoffs, workforce reduction, biotech, research organization, streamlining